Table 1.

Characteristics of the study population and screening utilization by race/ethnicity before and after the release of the 2021 United States Preventive Services Task Force CRC screening recommendation update

Patient characteristic	Prerecommendation population (April 2021)	Postrecommendation population (May 2021)			2 yr postrecommendation population (May 2023)
			Absolute differencea	Percent differencea		Absolute differencea	Percent differencea
Eligible patients	30,185	36,767	6,582	21.8%	39,204	9,019	29.9%
Age; mean, yr (SD)	61.6 (7.0)	59.2 (8.3)	n/a	n/a	59.5 (8.3)	n/a	n/a
	17,731 (58.7)	21,669 (58.9)	n/a	n/a	22,938 (58.5)	n/a	n/a
High school education or less; n (%)	8,224 (31.7)	9,622 (30.3)	n/a	n/a	9,750 (28.8)	n/a	n/a
Race; n (%)
Non-Hispanic White	21,520 (71.3)	25,764 (70.1)	4,244	19.7%	27,329 (69.7)	5,809	27.0%
Non-Hispanic Black	5,099 (16.9)	6,377 (17.3)	1,278	25.1%	6,962 (17.8)	1,863	36.5%
Hispanic	1,474 (4.9)	1,849 (5.0)	375	25.4%	1,728 (4.4)	254	17.2%
Non-Hispanic Asian	2,092 (6.9)	2,777 (7.6)	685	32.7%	3,185 (8.1)	1,093	52.2%
Percent up-to-date with CRC screening
Non-Hispanic White	72.1%	63.3%	n/a	−8.8%	64.4%	n/a	−7.7%
Non-Hispanic Black	67.1%	56.9%	n/a	−10.2%	57.9%	n/a	−9.2%
Hispanic	68.7%	58.2%	n/a	−10.5%	61.1%	n/a	−7.6%
Non-Hispanic Asian	69.2%	55.7%	n/a	−13.5%	57.9%	n/a	−11.3%

CRC, colorectal cancer.

^aCompared with April 2021.